(VIANEWS) – Shares of CARASENT (CARA.OL) plunged 11.85% at 15:43 EST Wednesday, continuing their steep drop since last session and prolonging a bearish trend for the Oslo Bors Benchmark Index_GI (GI: OSEIX), currently down 0.27% to 1,269.31; CARASENT’s last closing price stood at KR14.52 representing an 83.86% drop since hitting their 52-week high of KR23.65 on March 19th 2019.
About CARASENT
Carasent ASA is one of the premier cloud-based medical record services providers in Scandinavia. Webdoc offers several core solutions: an EHR system; Vardrummet is an interactive communication platform between patients and therapists; Ad Curis provides journal and professional system for rehabilitation, substance abuse treatment, mental health care as well as rehabilitation; Metodika EPM offers solutions for private clinics and hospitals; while Plustoo allows businesses to collaborate on occupational health projects collaboratively. They provide video solutions such as Confrere for physicians and Ad Voca and Ad Opus as follow-up systems for companies working towards inclusion. Carasent was established in 1997 in Oslo, Norway under its previous name – Apptix ASA; this name changed to Carasent ASA on May 2019.
Yearly Analysis
CARASENT’s stock is currently trading below its 52-week low, signaling an excellent buying opportunity for investors who see potential in its long-term prospects. CARASENT anticipates sales growth of 30.3% this year and 18.1% next year, suggesting they could generate higher revenues going forward.
However, an EBITDA figure of 2.54 suggests that earnings before taxes, depreciation and amortization (EBIDTA) for this company may still be relatively low, suggesting it hasn’t reached profitability yet. Investors should take this factor into account when assessing financial health and potential growth of this firm.
Overall, investors who have an optimistic view of CARASENT’s growth prospects and think its financials will improve may want to consider investing in its stock. Before making any final decisions about investing, however, it is crucial that extensive research be conducted in order to fully comprehend its finances and business prospects.
Technical Analysis
CARASENT stock has been performing poorly, with its current value dropping significantly below both its 50-day and 200-day moving averages. Furthermore, its last reported volume of 334,011 was significantly greater than its average volume of 40,933, signalling increased trading activity.
Since January 1st, the stock’s volatility has been relatively consistent; its intraday variation average is currently positive 0.46% for the last week – this bodes well for investors, as it indicates some degree of stability for this particular investment.
However, its stochastic oscillator indicates that it is currently oversold with a reading of =20. While this could signal that it could experience a rebound soon enough, investors should still proceed with caution and analyze each company carefully prior to making investment decisions.
Overall, CARASENT stock represents a high-risk investment at this time. While its high trading activity and stable volatility could be seen as promising indicators, its oversold status and low value compared to moving averages are cause for alarm. Investors should do further research and carefully consider their risk tolerance before investing in CARASENT.
Quarter Analysis
Investment Outlook for CARASENT | Carassent
CARASENT has demonstrated strong sales growth over time, including an estimated 32.3% rise for this quarter and 19.4% for next. Yet its current and subsequent quarter’s estimates for growth are both significantly negative; at 62.5% and 83.3% respectively – suggesting revenue may be slowing. This may cause investors to worry.
CARASENT’s year-over-year revenue growth estimates may have decreased, yet their quarterly revenue growth still exceeded their predictions by 35.8% year-on-year – this reflected in their current revenues of 227.09M which shows an impressive uptick from last year.
However, investors should carefully evaluate CARASENT’s profitability and financial health before making investment decisions. Although revenue growth might appear impressive at first glance, if it cannot sustain profitability over time it will not remain an attractive growth model for long-term investing success.
Though CARASENT’s sales growth may be encouraging, investors must exercise caution and perform extensive due diligence on its financial health and profitability before making investment decisions involving CARASENT. Investors must carefully consider both potential rewards as well as risks involved with investing in CARASENT before deciding to do so.
Your browser does not support CSS. Click Here for details.
Equity Analysis
Based on available information, CARASENT’s trailing twelve month earnings per share (EPS) stands at kr-0.63, suggesting that it does not currently generate positive earnings per share.
CARASENT has reported an ROE of negative 4.05% over its most recent twelve-month period, suggesting it is not efficiently using shareholder equity to generate profits and generating returns for shareholders.
Investors should proceed with caution when considering investing in companies with negative earnings and ROE. Prior to making any decisions about investing, further investigate their finances and operations as well as any possible improvements that might take place before taking any actions.
More news about CARASENT (CARA.OL).
